GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -4.2% ·
share flow -1.6% ·
net new positions -8.7%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | — |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | — | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | — | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | — | — |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | — |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | — | — |
| Q2 2024 | 18 | — | 202.41M | $13.88B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 118.98M | -0.3% | $13.21B | 0.2% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 116.28M | +1.2% | $12.91B | 0.2% | ▲ Add | 2 | SEC ↗ ×24 |
| 3 | Fidelity (FMR) ✦ | 60.32M | +0.6% | $6.70B | 0.3% | ▲ Add | 2 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (passive) | 59.09M | -0.2% | $6.56B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 5 | Capital World Investors ✦ | 45.18M | -2.4% | $5.02B | 0.7% | ▼ Trim | 6 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 42.33M | — | $4.70B | 0.1% | n/c | 1 | SEC ↗ ×42 |
| 7 | Dodge & Cox ✦ | 30.13M | -2.2% | $3.34B | 1.8% | ▼ Trim | 6 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 29.93M | +2.5% | $3.31B | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | T. Rowe Price ✦ | 26.50M | +12.4% | $2.94B | 0.3% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 25.62M | -31.7% | $2.84B | 0.5% | ▼ Trim | 6 | SEC ↗ ×9 |
| 11 | Morgan Stanley ✦ | 23.73M | — | $2.63B | 0.2% | n/c | 1 | SEC ↗ ×23 |
| 12 | Goldman Sachs Group ✦ | 7.12M | — | $790.52M | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 13 | Renaissance Technologies ✦ | 5.46M | -3.6% | $606.36M | 0.8% | ▼ Trim | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 5.21M | -4.8% | $578.05M | 0.5% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | AQR Capital Management ✦ | 2.38M | -3.7% | $264.13M | 0.2% | ▼ Trim | 6 | SEC ↗ ×7 |
| 16 | Marshall Wace ✦ | 1.90M | -2.5% | $211.06M | 0.2% | ▼ Trim | 6 | SEC ↗ ×3 |
| 17 | Adage Capital Partners ✦ | 1.36M | -6.7% | $150.43M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 658.66K | +54.4% | $73.11M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 19 | Millennium Management ✦ | 632.69K | -17.2% | $70.23M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 413.76K | -40.9% | $45.93M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 385.36K | -42.2% | $42.78M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 345.90K | +22.6% | $38.39M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 23 | Fisher Asset Management ✦ | 26.05K | +143.5% | $2.89M | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $2.15B | was 0.3% |
| Point72 Asset Management | $18.26M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 61.30K shares, $8,543 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.60K sh · $229,907
Officer · 600 sh · $87,174
Officer · 800 sh · $115,566
Officer · 3.00K sh · $435,870
Officer, Director · 7.99K sh · $1.19M
Officer, Director · 1.60K sh · $236,014
Officer, Director · 5.41K sh · $807,856
Director · 3.40K sh · $504,296
Director · 3.12K sh · $462,432
Director · 4.60K sh · $684,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology